About Tempus AI, Inc. - Class A Common Stock (TEM)
Tempus AI, Inc. is a technology company focused on leveraging artificial intelligence to revolutionize the healthcare industry. The company specializes in developing data-driven solutions that provide advanced analytics and insights for precision medicine, enhancing patient care by integrating clinical and molecular data. Tempus works with healthcare providers, researchers, and pharmaceutical companies to streamline the process of matching patients with tailored treatments, ultimately aiming to improve health outcomes and accelerate advancements in medical research. By harnessing the power of machine learning and vast datasets, Tempus is at the forefront of transforming healthcare practices and fostering innovation in the medical field. Read More
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025.
Tempus AI stock shows strong technical momentum and high revenue growth, making it a top candidate for growth investors using a systematic screening method.
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference on Thursday, November 13 in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:00 AM ET.
Cathie Wood's Ark Invest made significant trades involving BABA, BIDU, AMD, and TEM, reflecting their strategic positioning in tech. They purchased BABA and BIDU shares, while selling shares of AMD and TEM, aligning with recent advancements and partnerships in the respective companies. Additionally, they sold shares of SOFI and Roku.
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET.
The company, which specializes in artificial intelligence (AI) functionalities to aid drug discovery, could be a powerhouse, according to one market professional.
Tempus AI (NASDAQ:TEM) shares are trading higher Monday after the company announced its subsidiary, Ambry Genetics, published a peer reviewed study in Genetics in Medicine.
October 20, 2025 - The artificial intelligence (AI) sector continues to be a dominant force in the financial markets, driving significant gains and pushing major indices to new highs. Despite a backdrop of global economic uncertainty and geopolitical tensions, AI-related stocks have demonstrated exceptional performance throughout 2025, with some companies
Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in Genetics in Medicine (GIM), the official journal of the American College of Medical Genetics and Genomics (ACMG). The ACMG is a national organization bringing together experts in medical genetics to improve patient care and to support fair access to genetic services. The study presents a comprehensive analysis of 10 years of exome reanalysis data across diverse racial, ethnic, and ancestral (REA) groups.
Top large-cap losers last week included IonQ, Tempus AI, AeroVironment, Astera Labs, Nebius, Kratos, F5, Klarna, Leonardo DRS, and First Horizon, driven by sector pullbacks, policy concerns on defense buybacks, a high-profile cyber breach, and weak earnings.
Whitehawk Therapeutics shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI to support the development of its oncology pipeline.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus’ proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics’ oncology pipeline.
After hitting $100, Tempus AI has retreated, but shares have still provided huge returns. Multiple factors suggest that the stock could see a larger correction.
